Method of electroporation mediated delivery of drugs and genes

• US 6,233,482 B1
• Filed: 11/09/1998
• Issued: 05/15/2001
• Est. Priority Date: 08/01/1997
• Status: Expired due to Term

• Current Assignee: Oncosec Medical Incorporated (China Grand Pharmaceutical & Healthcare Holdings Ltd.)
• Original Assignee: Genetronics, Inc. (Inovio Pharmaceuticals, Inc.)
• Inventors: Levatter, Jeffrey I., Dimmer, Steven C., Hofmann, Gunter A., Dev, Sukhendu B., Nanda, Gurvinder S.
• Primary Examiner(s): KENNEDY, SHARON E
• Application Number:
  US09/189,062
• Time in Patent Office: 918 Days
• Field of Search: 604/890.1, 604/19-22, 604/500, 604/501, 128/898, 607/2, 607/100, 607/115, 607/154, 607/68-74, 435/173.5, 435/173.6
• US Class Current: 604/21
• CPC Class Codes: A61N 1/0502 Skin piercing electrodes
• CPC Class Codes: A61N 1/325 for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body electrodes for external use A61N1/0428
• CPC Class Codes: A61N 1/327 for enhancing the absorption properties of tissue, e.g. by electroporation
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

A method and apparatus for in vivo electroporation therapy. Using electroporation therapy (EPT) as described in the invention, tumors treated by a combination of electroporation using the apparatus of the invention and a chemotherapeutic agent caused regression of tumors in vivo. In one embodiment, the invention provides a method of EPT utilizing low voltage and long pulse length for inducing cell death. One embodiment of the invention includes a system for clinical electroporation that includes a needle array electrode having a “keying” element that determines the set point of the therapy voltage pulse and/or selectable array switching patterns. A number of electrode applicator designs permit access to and treatment of a variety of tissue sites. Another embodiment provides a laparoscopic needle applicator that is preferably combined with an endoscope for minimally invasive EPT.

Claims

1. A method for the therapeutic application of electroporation to a tissue of a subject for introducing molecules into cells therein, comprising:

a) providing a system for electroporation comprising the following components in electrical communication;

(i) an electrode applicator having at least two opposing pairs of electrodes, wherein at least one of the electrodes comprises a needle electrode for penetrating tissue and introducing molecules into the tissue;

(ii) at least one identification element for providing information about the electrode applicator to the system;

(iii) a variable power supply to selectively supply voltage pulses to the electrodes; and

(iv) at least one switching element in electrical communication with each electrode,

wherein the switching element directs pulses of opposite polarity voltage to selected opposing pairs of electrodes;

b) introducing molecules into selected tissue through the at least one needle electrode;

c) positioning the at least two opposing pairs of electrodes in conductive relation to the selected tissue; and

d) simultaneously applying the opposite polarity voltage pulses to the selected opposing electrode pairs;

wherein the applied voltage is proportionate to the distance between the electrode pairs, thereby causing electroporation of the tissue and introducing the molecules into the cells therein.

2. The method of claim 1, wherein the method is in vitro.

3. The method of claim 1, wherein the method is in vivo.

4. The method of claim 1, wherein the method is ex vivo.

5. The method of claim 1, wherein the subject is a mammal.

6. The method of claim 1, wherein the subject is a human.

7. The method of claim 1, wherein the molecule is selected from the group consisting of a chemotherapeutic agent, a polynucleotide and a polypeptide.

8. The method of claim 1, wherein the molecule is introduced by a method selected from the group consisting of intratumorally, systemically and locally.

9. The method of claim 7, wherein the chemotherapeutic agent is selected from the group consisting of bleomycin, neocarcinostatin, carboplatin, suramin, doxorubicin, mitomycin C and cisplatin.

10. The method of claim 1, wherein the tissue is selected from the group consisting of pancreas, larynx, nasopharynx, hypopharynx, oropharynx, lip, throat, lung, heart, kidney, muscle, breast, colon, prostate, thymus, testis, skin, and ovary.

11. The method of claim 10, wherein the tissue is pancreas.

12. The method of claim 10, wherein the tissue is a tissue of a head and neck cancer.

13. The method of claim 12, wherein the tissue is larynx, nasopharynx, hypopharynx, lip, or throat tissue.

14. The method of claim 1, wherein the pulses establish a nominal electric field of about 10 V/cm to 1300 V/cm.

15. The method of claim 1, wherein the pulses establish a nominal electric field of about 25 V/cm to 75 V/cm.

16. The method of claim 1, wherein the pulses establish a nominal electric field of about 1000 V/cm to 1300 V/cm.

17. The method of claim 1, wherein the pulse length is from about 5 μ

sec to 99 msec.

19. The method of claim 1 or 18, wherein there are three opposing pairs of electrodes forming a hexagon.

20. The method of claim 1 or 18, wherein there are four opposing pairs of electrodes forming an octagon.

21. The method of claim 1 or 18, wherein there are two opposing pairs of electrodes forming a square.

22. The method of claim 1 or 18 wherein the information provided to the system by the identification element is the number of needles, needle spacing, needle array geometry, needle switching sequence, voltage set point, pulse length, pulse shape, electrode shelf life, electrode use, error code capture, lockout features, or a combination of any two or more thereof.

18. A method for the in vivo electroporation therapy of a cell of a subject comprising:

a) providing a system for electroporation comprising in electrical communication;

an electrode applicator having at least two opposing pairs of electrodes, wherein at least one of the electrodes comprises a needle electrode for penetrating tissue and introducing molecules into the tissue;

(ii) at least one identification element for providing information about the electrode applicator to the system;

(iii) a variable power supply to selectively supply voltage pulses to the electrodes; and

(iv) at least one switching element in electrical communication with each electrode,

wherein the switching element directs pulses of opposite polarity voltage to selected opposing pairs of electrodes;

b) introducing a therapeutic composition into cells in selected tissue through the at least one needle electrode;

c) positioning the at least two opposing pairs of electrodes in conductive relation to the selected tissue; and

d) simultaneously applying the opposite polarity voltage pulses to the selected opposing electrode pairs

wherein the applied voltage is proportionate to the distance between the electrode pairs, thereby causing in vivo electroporation of the tissue and introducing the therapeutic composition into the cells therein.

23. A method for the therapeutic application of electroporation to a tissue of a subject for introducing molecules into cells therein, comprising:

a) providing a system for electroporation comprising the following components in electrical communication;

(i) an electrode applicator having at least two opposing pairs of electrodes;

(ii) at least one identification element that provides information about the electrode applicator to the system;

(iii) a power supply to selectively apply voltage pulses to the system; and

(iv) at least one switching element in electrical communication with each electrode,

wherein the switching element selectively directs the voltage pulses to the at least two pairs of electrodes;

b) inserting at least a first pair of the opposing electrodes into selected tissue of the subject;

c) positioning at least a second pair of the opposing electrodes in conductive relation to the selected tissue;

d) introducing molecules into the tissue; and

e) applying the opposite polarity voltage pulses to the selected opposing electrode pairs, thereby causing electroporation of the tissue and introducing the molecules into the cells therein.

24. The method of claim 23, wherein the method is in vitro.

25. The method of claim 23, wherein the method is in vivo.

26. The method of claim 23, wherein the method is ex vivo.

27. The method of claim 23, wherein the subject is a mammal.

28. The method of claim 23, wherein the subject is a human.

29. The method of claim 23, wherein the molecule is selected from the group consisting of a chemotherapeutic agent, a polynucleotide and a polypeptide.

30. The method of claim 23, wherein the molecules are introduced by a method selected from the group consisting of intratumorally, systemically and locally.

31. The method of claim 30, wherein the chemotherapeutic agent is selected from the group consisting of bleomycin, neocarcinostatin, carboplatin, suramin, doxorubicin, mitomycin C and cisplatin.

32. The method of claim 23, wherein the tissue is selected from the group consisting of pancreas, larynx, nasopharynx, hypopharynx, oropharynx, lip, throat, lung, heart, kidney, muscle, breast, colon, prostate, thymus, testis, skin, and ovary.

33. The method of claim 32, wherein the tissue is pancreas.

34. The method of claim 32, wherein the tissue is a tissue of a head and neck cancer.

35. The method of claim 32, wherein the tissue is larynx, nasopharynx, hypopharynx, lip, or throat tissue.

36. The method of claim 23, wherein the pulses establish a nominal electric field of about 10 V/cm to 1300 V/cm.

37. The method of claim 23, wherein the pulses establish a nominal electric field of about 25 V/cm to 75 V/cm.

38. The method of claim 23, wherein the pulses establish a nominal field of about 1000 V/cm to 1300 V/cm.

39. The method of claim 23, wherein the pulse length is from about 5 μ

sec to 99 msec.

40. The method of claim 23, wherein there are three opposing pairs of electrodes forming a hexagon.

41. The method of claim 23, wherein there are four opposing pairs of electrodes forming an octagon.

42. The method of claim 23, wherein there are two opposing pairs of electrodes forming a square.

43. The method of claim 23 wherein the information provided to the system by the identification element is the number of needles in the electrode applicator.

44. The method of claim 23 wherein the information provided to the system by the identification element is the number of needles, needle spacing, needle array geometry, needle switching sequence, voltage set point, pulse length, pulse shape, electrode shelf life, electrode use, error code capture, lockout features, or a combination of any two or more thereof.